Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Conditions

• Non-Small Cell Lung Cancer
• Head and Neck Squamous Cell Carcinoma
• Micro Satellite Stable Colorectal Cancer
• Gastric/Esophageal Cancer
• High-Grade Serous Ovarian Cancer
• Pancreatic Cancer
• Triple Negative Breast Cancer

Interventions

• DRUG: Azirkitug
• DRUG: Budigalimab
• DRUG: Bevacizumab
• DRUG: Telisotuzumab Adizutecan

Sponsor

AbbVie